Could this mRNA shot stop the virus behind mono and cancer?
NCT ID NCT07478952
First seen Mar 19, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This early-stage study is testing a new mRNA vaccine called mRNA-1189 to see if it is safe and can protect against Epstein-Barr virus (EBV). About 120 healthy adults aged 18 to 30 will receive the vaccine either under the skin or into a muscle. Researchers will monitor side effects and measure the body's immune response to the vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN BARR VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
NOT_YET_RECRUITINGMelbourne, Victoria, VIC 3149, Australia
-
Nucleus Network
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.